Why NovoCure Stock Is Falling Today

Shares of the novel oncology company NovoCure (NASDAQ: NVCR) are trading lower today following the company's 2022 fourth-quarter and full-year results release this morning. Although the company's financial results were essentially in line with Wall Street's consensus estimates for the three-month period, investors were clearly looking for a stronger quarter from the cancer company. Perhaps the most concerning issue is that NovoCure's net revenue fell by 4% in Q4 to $128.4 million, relative to the same period a year ago.